The Diet Gout Trial (DIGO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03569020|
Recruitment Status : Recruiting
First Posted : June 25, 2018
Last Update Posted : August 6, 2018
|Condition or disease||Intervention/treatment||Phase|
|Gout Hyperuricemia||Other: Subsidy for food purchases and dietitian education||Not Applicable|
The public health burden of gout is substantial. Several lines of evidence suggest that a DASH diet might lower uric acid. However, there are no trials of the DASH diet in adults with gout. This trial is a cross-over study of the effects of a DASH-like diet on uric acid in adults with gout and hyperuricemia, who are not taking urate-lowering therapy.
Perpetuated by the "Western" lifestyle and resulting obesity epidemic, the prevalence of gout has increased over the past few decades to 3.9% of US adults (8.3 million individuals). This prevalence increases with age to 9.3% of US adults over 60 years (4.7 million).
Participants will be community-dwelling adults, aged 18+ with a baseline serum uric acid level of 7 mg/dL, who have a self-reported history of gout and are not taking urate lowering medications (e.g. allopurinol, febuxostat, probenecid).
This trial is comprised of two study periods: (1) a dietitian-directed diet (DD) or (2) self-directed usual diet (SD). Each period lasts 4 weeks. All participants will participate in both periods, but half will undergo the dietitian-directed diet first while the other half will undergo the self-directed diet first. During the dietitian-directed diet, participants will receive $105/week of foods in a pattern that conforms to the DASH diet. The DASH diet emphasizes fruit, vegetables, lean meat, low fat dairy, and high fiber, while restricting red meat, sweets, and sugary beverages. During the self-directed diet, participants will be asked to eat their typical diet outside of the study. Investigators anticipate 40 participants in this study.
The primary outcome is uric acid. Secondary outcomes of this study include: body mass index, systolic and diastolic blood pressure, fasting cholesterol, and fasting blood glucose. Both primary and secondary outcomes will be measured 3 times: (1) before the study begins (baseline), (2) after period 1 (at 4 weeks), and (3) after period 2 (at 8 weeks). Patient-reported outcomes, dietary compliance, and urine electrolytes will be assessed throughout the study as well.
The primary comparison will be serum uric acid concentrations measured after the 4-week dietitian-directed diet versus uric acid concentrations measured after the 4-week self-directed diet (DD vs. SD). Comparisons will be made within person using generalized estimating equations (GEE) with and without adjustment for baseline uric acid concentration. Investigators will use GEE models for secondary outcomes as well.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Half of participants will be randomly assigned 1 of 2 potential sequences. All participants will ultimately participate in each study period, but the order will be randomly assigned 1:1.|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Masking Description:||Investigators will not know which assignment the participants were given. The laboratory measuring uric acid will not know which intervention the participants were assigned.|
|Official Title:||Dietary Approaches to Stop Hypertension (DASH) Diet Effects on Serum Uric Acid (SUA) in Adults With Hyperuricemia and Gout|
|Actual Study Start Date :||June 15, 2018|
|Estimated Primary Completion Date :||February 15, 2019|
|Estimated Study Completion Date :||June 30, 2019|
Experimental: Dietitian-Directed Diet
Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
Other: Subsidy for food purchases and dietitian education
$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
No Intervention: Self-Directed Diet
Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
- Uric acid level [ Time Frame: Baseline ]Measured in serum
- Uric acid level [ Time Frame: At 4-weeks ]Measured in serum
- Uric acid level [ Time Frame: At 8-weeks ]Measured in serum
- Blood pressure as assessed by systolic and diastolic blood pressure [ Time Frame: Baseline ]
- Blood pressure as assessed by systolic and diastolic blood pressure [ Time Frame: At 4-weeks ]
- Blood pressure as assessed by systolic and diastolic blood pressure [ Time Frame: At 8-weeks ]
- Change in Fasting blood glucose [ Time Frame: Baseline, 4-weeks, 8-weeks ]Measured in serum
- Change in Fasting lipid panel [ Time Frame: Baseline, 4-weeks, 8-weeks ]Measured in serum
- Change in Body mass index [ Time Frame: Baseline, 4-weeks, 8-weeks ]Derived from baseline height, and serial weight measurements
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03569020
|United States, Maryland|
|Johns Hopkins ProHealth Research Clinic||Recruiting|
|Woodlawn, Maryland, United States, 21207|
|Contact: Jeanne Charleston, RN 410-281-1600 firstname.lastname@example.org|
|Contact: Beiwen Wu, MSPH 410-281-1600 email@example.com|
|Principal Investigator: Edgar R Miller, MD, PhD|
|Sub-Investigator: Stephen P Juraschek, MD, PhD|
|United States, Massachusetts|
|Massachusetts General Hospital||Active, not recruiting|
|Boston, Massachusetts, United States, 02114|